Story perspectives
Veradermics Seeks FDA Approval for Oral Hair Loss Treatment
10/17/2025
45 7
1 of 1
Story summary
- Veradermics is developing VDPHL01, an extended-release oral minoxidil for androgenetic alopecia in men and women, an approach that could affect 80 million people in the United States if approved.
- Veradermics plans to submit for FDA approval based on ongoing positive trial data.
- Minoxidil is FDA-approved only for topical use.
- Finasteride is approved only for men.
